Is Mersana Therapeutics (NASDAQ:MRSN) Weighed On By Its Debt Load?

Simply Wall StDec 17 20:08

Alphina Therapeutics Strengthens Management Team With Appointment of Marc Damelin, Ph.D. as Chief Scientific Officer

PR NewswireDec 17 20:00

BTIG Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $6

Futu NewsDec 17 09:32 · Ratings

Promising Clinical Data and Valuation Support Mersana Therapeutics' Buy Recommendation

TipRanksDec 17 08:47

Citi Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Cuts Target Price to $5

Futu NewsNov 15 18:34 · Ratings

Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)

TipRanksNov 15 18:31 · Ratings